Akouos' Hearing Loss Gene Therapy Poised To Receive Orphan Drug Tag In Europe

by Vandana Singh, Benzinga Editor
August 11, 2021 2:58 PM | 26 seconds read | Make a Comment
Loading...
Loading...
  • The European Medicines Agency (EMA) Committee for Orphan Medicinal Products has issued a positive opinion on Akouos Inc's AKUS application for orphan drug designation for AK-OTOF.
  • AK-OTOF is a gene therapy intended for the treatment of otoferlin gene-mediated hearing loss. 
  • The FDA previously granted AK-OTOF Orphan Drug Designation and Rare Pediatric Disease Designation for this same indication.
  • Price Action: AKUS shares are down 4.30% at $11.80 during the market session on the last check Wednesday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In: BiotechNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefsEuropean Medicines Agency (EMA)gene therapyOrphan Drug Designation
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!